Bayesian Analysis

Bayesian Two-Stage Design for Phase II Clinical Trials with Switching Hypothesis Tests

Haolun Shi and Guosheng Yin

Full-text: Open access


Conventional phase II clinical trials use either a single-arm or a double-arm scheme to examine the treatment effect of an investigational drug. The hypotheses tests under these two schemes are different, as a single-arm study usually tests the response rate of the new drug against a set of fixed reference rates and a double-arm randomized trial compares the new drug with the standard treatment or placebo. To bridge the single- and double-arm schemes in one phase II clinical trial, we propose a Bayesian two-stage design with changing hypothesis tests. Stage 1 enrolls patients solely to the experimental arm to make a comparison with the reference rates, and stage 2 imposes a double-arm comparison of the experimental arm with the control arm. The design is calibrated with respect to error rates from both the frequentist and Bayesian perspectives. Moreover, we control the “type III error rate”, defined as the probability of prematurely stopping the trial at stage 1 when the trial is supposed to move on to stage 2. We conduct extensive simulations on the calculations of these error rates to examine the operational characteristics of our proposed method, and illustrate it with a non-small cell lung cancer trial.

Article information

Bayesian Anal., Volume 12, Number 1 (2017), 31-51.

First available in Project Euclid: 18 December 2015

Permanent link to this document

Digital Object Identifier

Mathematical Reviews number (MathSciNet)

Zentralblatt MATH identifier

Primary: 62C10: Bayesian problems; characterization of Bayes procedures
Secondary: 62P10: Applications to biology and medical sciences

Bayesian error rates expected sample size phase II clinical trial single-to-double arm design two-stage procedure type I error type II error


Shi, Haolun; Yin, Guosheng. Bayesian Two-Stage Design for Phase II Clinical Trials with Switching Hypothesis Tests. Bayesian Anal. 12 (2017), no. 1, 31--51. doi:10.1214/15-BA988.

Export citation


  • Chang, M. N., Therneau, T. M., Wieand, H. S., and Cha, S. S. (1987). “Designs for group sequential phase II clinical trials.” Biometrics, 43(4): 865–874.
  • Chen, T. and Ng, T.-H. (1998). “Optimal flexible designs in phase II clinical trials.” Statistics in Medicine, 17(20): 2301–2312.
  • Dong, G., Shih, W. J., Moore, D., Quan, H., and Marcella, S. (2012). “A Bayesian-frequentist two-stage single-arm phase II clinical trial design.” Statistics in Medicine, 31(19): 2055–2067.
  • Fleming, T. R. (1982). “One-sample multiple testing procedures for phase II clinical trials.” Biometrics, 38(1): 143–151.
  • Gehan, E. A. (1961). “The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.” Journal of Chronic Diseases, 13(4): 346–353.
  • Green, S. J. and Dahlberg, S. (1992). “Planned versus attained design in phase II clinical trials.” Statistics in Medicine, 11(7): 853–862.
  • Hobbs, B. P., Carlin, B. P., Mandrekar, S. J., and Sargent, D. J. (2011). “Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials.” Biometrics, 67(3): 1047–1056.
  • Hobbs, B. P., Sargent, D. J., and Carlin, B. P. (2012). “Commensurate priors for incorporating historical information in clinical trials using general and generalized linear models.” Bayesian Analysis, 7(3): 639–674.
  • Inoue, L. Y., Thall, P. F., and Berry, D. A. (2002). “Seamlessly expanding a randomized phase II trial to phase III.” Biometrics, 58(4): 823–831.
  • Lai, T. L., Lavori, P. W., and Shih, M. C. (2012). “Sequential design of phase II–III cancer trials.” Statistics in Medicine, 31(18): 1944–1960.
  • Lee, J. J. and Liu, D. D. (2008). “A predictive probability design for phase II cancer clinical trials.” Clinical Trials, 5(2): 93–106.
  • Lee, S. J. and Zelen, M. (2000). “Clinical Trials and sample size considerations: another perspective (with discussion).” Statistical Science, 15(2): 95–100.
  • Liu, J. F., Lin, Y., and Shih, W. J. (2010). “On Simon’s two-stage design for single-arm phase IIA cancer clinical trials under beta–binomial distribution.” Statistics in Medicine, 29(10): 1084–1095.
  • Mariani, L. and Marubini, E. (1996). “Design and analysis of phase II cancer trials: a review of statistical methods and guidelines for medical researchers.” International Statistical Review, 64(1): 61–88.
  • Mayo, M. S. and Gajewski, B. J. (2004). “Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.” Controlled Clinical Trials, 25(2): 157–167.
  • Posch, M., Koenig, F., Branson, M., Brannath, W., Dunger-Baldauf, C., and Bauer, P. (2005). “Testing and estimation in flexible group sequential designs with adaptive treatment selection.” Statistics in Medicine, 24(24): 3697–3714.
  • Sambucini, V. (2008). “A Bayesian predictive two-stage design for phase II clinical trials.” Statistics in Medicine, 27(8): 1199–1224.
  • Sambucini, V. (2010). “A Bayesian predictive strategy for an adaptive two-stage design in phase II clinical trials.” Statistics in Medicine, 29(13): 1430–1442.
  • Shi, H. and Yin, G. (2015). “Supplementary Material of Bayesian Two-Stage Design for Phase II Clinical Trials with Switching Hypothesis Tests” Bayesian Analysis.
  • Simon, R. (1989). “Optimal two-stage designs for phase II clinical trials.” Controlled Clinical Trials, 10(1): 1–10.
  • Simon, R., Wittes, R. E., and Ellenberg, S. S. (1985). “Randomized phase II clinical trials.” Cancer Treatment Reports, 69(12): 1375–1381.
  • Steinberg, S. M. and Venzon, D. J. (2002). “Early selection in a randomized phase II clinical trial.” Statistics in Medicine, 21(12): 1711–1726.
  • Storer, B. E. (1992). “A class of phase II designs with three possible outcomes.” Biometrics, 48(1): 55–60.
  • Sylvester, R. J. (1988). “A Bayesian approach to the design of phase II clinical trials.” Biometrics, 44(3): 823–836.
  • Tan, S. B. and Machin, D. (2002). “Bayesian two-stage designs for phase II clinical trials.” Statistics in Medicine, 21(14): 1991–2012.
  • Thall, P. F. and Simon, R. (1994). “Practical Bayesian guidelines for phase IIB clinical trials.” Biometrics, 50(2): 337–349.
  • Thall, P. F. and Simon, R. (1995). “Recent developments in the design of phase II clinical trials.” Cancer Treatment and Research, 75(2): 49–71.
  • Viele, K., Berry, S., Neuenschwander, B., Amzal, B., Chen, F., Enas, N., Hobbs, B., Ibrahim, J. G., Kinnersley, N., Lindborg, S., Micallef, S., Roychoudhury, S., and Thompson, L. (2014). “Use of historical control data for assessing treatment effects in clinical trials.” Pharmaceutical Statistics, 13(1): 41–54.
  • Wang, Y. G., Leung, D. H., Li, M., and Tan, S. B. (2005). “Bayesian designs with frequentist and Bayesian error rate considerations.” Statistical Methods in Medical Research, 14(1): 445–456.
  • Yin, G. (2012). Clinical Trial Design: Bayesian and Frequentist Adaptive Methods. New York: John Willey & Sons, Inc.
  • Yin, G., Chen, N., and Lee, J. J. (2011). “Phase II trial design with Bayesian adaptive randomization and predictive probability.” Journal of the Royal Statistical Society: Series C (Applied Statistics), 61(5): 219–235.

Supplemental materials